Erythromycin: Nursing Drug Guide, CYP3A4 Interactions & NCLEX Review
Healthcare medication guide: erythromycin inhibits CYP3A4—before every dose complete medication reconciliation for theophylline, simvastatin, warfarin, and QT-prolonging drugs; hold and escalate for toxicity cues.
Labeling identifies erythromycin as a moderate CYP3A4 inhibitor. Co-administration can raise levels of theophylline, simvastatin/lovastatin, colchicine, warfarin, and digoxin—with reports of theophylline toxicity, rhabdomyolysis, and increased anticoagulant effect. Erythromycin also prolongs the QT interval with postmarketing torsades de pointes (fatalities reported). Before every dose, complete medication reconciliation, screen QT-prolonging MAR entries and electrolytes, and hold plus escalate for tremor, palpitations, muscle pain, jaundice, or watery diarrhea with fever.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before the first and each subsequent dose, screen macrolide allergy, CYP3A4 substrates on the MAR (theophylline, statins, warfarin, colchicine), QT risk, and electrolytes. Hold erythromycin and notify the prescriber or pharmacist for theophylline toxicity signs, rhabdomyolysis symptoms, supratherapeutic INR, QT symptoms, hepatitis, serious rash, or watery diarrhea with fever.
Most common brand names
Erythromycin is available as oral tablets (250 mg and 500 mg base), oral suspension, delayed-release forms (Ery-Tab), and IV erythromycin lactobionate in some markets. Verify product, route, and strength on the MAR—oral and IV formulations are not interchangeable without a new order.
Cross-hypersensitivity among macrolides is possible; compare interaction profiles with azithromycin when selecting alternatives—erythromycin carries stronger CYP3A4 inhibition than azithromycin per labeling.
Why we give it — Indications
FDA labeling indicates erythromycin for infections caused by susceptible organisms. Nurses encounter it for upper and lower respiratory tract infections, pneumonia due to Mycoplasma pneumoniae, skin and soft-tissue infections, pertussis, diphtheria (adjunct to antitoxin), Legionnaires’ disease, and Chlamydia / Ureaplasma infections when tetracyclines are contraindicated. It remains an option for penicillin-allergic patients in selected streptococcal infections per labeling.
| Use (labeling examples) | Detail |
|---|---|
| Upper / lower respiratory tract | Mild to moderate infections due to susceptible streptococci, pneumococci, or H. influenzae (often with sulfonamide when indicated) |
| Mycoplasma pneumonia | Respiratory tract infections due to Mycoplasma pneumoniae |
| Skin and soft tissue | Mild to moderate Streptococcus pyogenes or Staphylococcus aureus infections |
| Pertussis / diphtheria | Pertussis treatment or prophylaxis; diphtheria as adjunct to antitoxin per labeling |
| Chlamydia (when tetracyclines not used) | Urogenital, neonatal conjunctivitis, and pregnancy-related regimens per labeling |
On a small screen, swipe or scroll sideways to see the full table.
Labeling states erythromycin should be used only for proven or strongly suspected bacterial infections to limit resistance. Verify culture and susceptibility when available; institutional pathways may prefer other macrolides or agents with fewer interactions.
How it works
Erythromycin is a macrolide antibacterial that binds the 50S ribosomal subunit and inhibits bacterial protein synthesis. Nursing focus must include CYP3A4 inhibition: labeling describes erythromycin as a substrate and inhibitor of CYP3A, so co-administered drugs (theophylline, certain statins, warfarin, colchicine, digoxin) may reach toxic levels. Labeling also associates erythromycin with QT prolongation and torsades de pointes—screen cardiac risk and electrolytes on every pass.
Dosing overview
Verify indication, weight (pediatrics), and renal/hepatic status against current prescribing information. Doses below are from FDA erythromycin tablet labeling; pediatric weight-based tables are extensive—use pharmacy or the full label for complete pediatric regimens.
Selected special regimens (labeling)
| Indication | Dose | Duration |
|---|---|---|
| Streptococcal pharyngitis (adults/children) | Usual weight-based or adult tablet dose | At least 10 days per labeling |
| Rheumatic fever prophylaxis (penicillin-allergic) | 250 mg PO twice daily | Long-term per AHA guidance cited in labeling |
| Chlamydia in pregnancy (adults) | 500 mg four times daily on empty stomach | At least 7 days (or alternate 500 mg q12h / 250 mg QID × ≥14 days if intolerance) |
| Legionnaires’ disease | 1–4 g daily divided | Optimal duration not established in labeling |
On a small screen, swipe or scroll sideways to see the full table.
Renal adjustment: Not specified in the reviewed oral tablet prescribing information. Hepatic impairment: Use caution—erythromycin is principally excreted by the liver per labeling.
Missed dose: Not specified in the reviewed prescribing information. Do not double doses; contact pharmacy for guidance.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Absorption | Readily absorbed; interpatient variation | Optimal levels when given fasting (≥30 min, preferably 2 h before meals) per labeling |
| Distribution | Largely protein bound; crosses placenta; excreted in breast milk | Fetal levels low; caution in lactation per labeling |
| QT effect | Associated with QT prolongation; postmarketing torsades de pointes | Screen electrolytes and QT-prolonging co-therapy before each dose |
| Elimination | Concentrated in liver; excreted in bile; <5% active drug in urine | Not removed by dialysis; hepatic dysfunction increases risk per labeling |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Allergy history to erythromycin or other macrolides
- Medication reconciliation for CYP3A4 substrates: theophylline, aminophylline, simvastatin/lovastatin, colchicine, warfarin, digoxin
- Contraindicated co-therapy per labeling: terfenadine, astemizole, cisapride, pimozide, ergotamine, dihydroergotamine; lovastatin or simvastatin
- QT-prolonging MAR entries; cardiac history; potassium and magnesium on basic metabolic panel
- Myasthenia gravis history—exacerbation reported
- Neonates/infants: IHPS risk after erythromycin—teach caregivers to report vomiting or feeding irritability
Contraindications
- Known hypersensitivity to erythromycin
- Concomitant terfenadine, astemizole, cisapride, pimozide, ergotamine, or dihydroergotamine
- Concomitant lovastatin or simvastatin (CYP3A4 statins extensively metabolized)—rhabdomyolysis risk
Important interactions
| Drug / factor | Effect | Nursing action |
|---|---|---|
| Theophylline (high dose) | Increased serum theophylline; toxicity risk | Monitor level and toxicity signs; reduce theophylline per prescriber when toxicity occurs |
| Simvastatin / lovastatin | Contraindicated; rhabdomyolysis reported with other statins | Hold statin per labeling; monitor CK and muscle pain if interaction suspected |
| Colchicine | Increased colchicine levels; life-threatening toxicity reported | Monitor for colchicine toxicity; verify dose reduction if co-prescribed |
| Warfarin | Increased anticoagulant effect (more pronounced in elderly per labeling) | Monitor INR and bleeding |
| Digoxin | Elevated digoxin serum levels reported | Monitor digoxin level and toxicity signs |
| QT-prolonging drugs / low K or Mg | Torsades de pointes risk | Hold and clarify with pharmacy when significant risk factors present |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral tablets and suspension: May be given without regard to meals per labeling, but optimal blood levels occur in the fasting state (at least 30 minutes and preferably 2 hours before meals). Use medication administration rights; shake suspension well. Many regimens require four daily doses—verify spacing on the MAR.
- Confirm correct patient, drug, dose, route, time, and formulation (base vs ethylsuccinate vs delayed-release)
- Document administration and GI tolerance (nausea, vomiting) on the MAR
- Infants: labeling reports infantile hypertrophic pyloric stenosis (IHPS)—urgent evaluation for non-bilious vomiting or feeding irritability
IV erythromycin lactobionate: Used for selected severe infections per labeling (e.g., acute pelvic inflammatory disease step-down regimens). Follow institutional IV compatibility, infusion rate, and phlebitis monitoring protocols—detailed IV nursing parameters are not specified in the reviewed oral tablet prescribing information.
Expected therapeutic response
- Decreasing fever, improving cough, and reduced purulent respiratory secretions when treating susceptible respiratory infection
- Improving localized signs for skin or ENT infections per prescriber plan
- Stable vital signs and rhythm without new palpitations, dizziness, or syncope during therapy
- INR remains within prescriber goal when warfarin is co-prescribed
Red flags — Stop and act
Hold erythromycin and escalate immediately when serious toxicity is suspected.
- Palpitations, dizziness, syncope, or new arrhythmia—possible QT prolongation / torsades
- Signs of hepatitis: jaundice, dark urine, severe abdominal pain, profound fatigue—labeling requires immediate discontinuation
- Angioedema, bronchospasm, or systemic allergic reaction—possible anaphylaxis
- Serious skin reaction (rash progressing to mucosal involvement, blistering, or systemic symptoms)
- Watery diarrhea, abdominal pain, fever—evaluate for C. difficile colitis
- Worsening weakness or respiratory distress in myasthenia gravis
- Supratherapeutic INR or active bleeding on warfarin
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Diarrhea, nausea, vomiting, abdominal pain | Common in clinical trials | Supportive care; differentiate mild GI upset from CDAD or hepatitis |
| QT prolongation / arrhythmia | Postmarketing reports including torsades | Hold dose, obtain electrocardiogram (ECG) or rhythm strip per protocol, notify prescriber urgently |
| Hepatotoxicity | Severe and sometimes fatal cases reported | Stop drug, order liver function tests, notify prescriber immediately |
| Serious allergic / skin reactions | Includes angioedema, SJS, TEN, DRESS | Stop drug, treat per anaphylaxis or severe reaction protocol |
| CDAD | Reported with nearly all antibacterials | Isolation precautions per facility; stool studies per order |
| Myasthenia exacerbation | Reported postmarketing | Stop drug, notify neurology/prescriber, monitor respiratory status |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Labeling states that in case of overdosage, erythromycin should be discontinued. Overdosage should be handled with prompt elimination of unabsorbed drug and other appropriate measures.
Management
Discontinue erythromycin and provide supportive care per labeling. Erythromycin is not removed by peritoneal dialysis or hemodialysis. No specific antidote is listed in the reviewed prescribing information. Contact local poison control or toxicology services per facility protocol for severe overdose or interaction toxicity (e.g., theophylline, colchicine).
Look-alike / sound-alike and error prevention
- Erythromycin vs azithromycin—both macrolides but different interaction profiles; do not substitute without prescriber/pharmacy review
- Erythromycin vs erythromycin ethylsuccinate—confirm salt/formulation on MAR; strengths are not interchangeable milligram-for-milligram without pharmacy conversion
- Ery-Tab vs E.E.S.—delayed-release vs ethylsuccinate products; verify correct formulation
- QID scheduling—four-times-daily orders are easy to miss during busy shifts; use MAR alerts
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| CYP3A4 screen | Flag new theophylline, statin, colchicine, or warfarin orders started during erythromycin therapy |
| Theophylline patients | Watch tremor, tachycardia, vomiting—toxicity after erythromycin is a labeled interaction |
| Fasting timing | Give on empty stomach when ordered for optimal levels; document if given with food |
| GI teaching | Report watery diarrhea—not only expected macrolide stomach upset |
| Commonly missed | Continuing erythromycin after rising theophylline level; missing simvastatin contraindication on MAR |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults | Labeling notes greater sensitivity to torsades de pointes in some elderly patients |
| Cardiac disease / long QT | Higher fatal arrhythmia risk—avoid unless benefit clearly outweighs risk |
| Myasthenia gravis | Exacerbation and new myasthenic syndrome reported |
| Neonates / infants | IHPS reported (5–10% in some cohorts with prolonged courses)—urgent evaluation if vomiting or feeding irritability |
| Pregnancy | Animal studies show no teratogenicity at listed doses; observational studies report cardiovascular malformations after early pregnancy exposure—use only if clearly needed |
| Lactation | Excreted in human milk; caution in nursing women per labeling |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Heart rate, rhythm symptoms, blood pressure; ECG or QTc monitoring when ordered
- Electrolytes (potassium, magnesium) when QT risk factors or diuretics present
- Theophylline levels and toxicity signs when theophylline or aminophylline is concurrent
- INR when warfarin is concurrent; CK and muscle symptoms when statin interaction suspected
- GI tolerance, hydration, stool character; antibiotic-associated diarrhea evaluation if severe
- Liver function tests if hepatotoxicity suspected
Document
- CYP3A4 and QT screening completed before first dose
- QID doses given on time; any held doses with prescriber/pharmacist notification
- Patient teaching on GI effects, interaction symptoms, and when to seek urgent review
Patient teaching
- Take exactly as prescribed—including four-times-daily schedules if ordered; ask whether doses should be taken on an empty stomach
- Report palpitations, fainting, muscle pain, dark urine, yellowing skin or eyes, severe abdominal pain, tremor, or trouble breathing immediately
- Report watery diarrhea, blood in stool, or abdominal cramping—even after stopping the antibiotic
- Do not start new prescription, OTC, or herbal medicines without pharmacist review—erythromycin inhibits CYP3A4 per labeling
- Complete the course unless told to stop; do not share leftover antibiotics
- Breastfeeding patients: discuss risks and benefits with the prescriber—erythromycin is excreted in human milk per labeling
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known hypersensitivity to erythromycin
- Concomitant terfenadine, astemizole, cisapride, pimozide, ergotamine, dihydroergotamine, lovastatin, or simvastatin per labeling
- Rising theophylline level or toxicity signs (tremor, tachycardia, persistent vomiting) until MDT review
- New palpitations, syncope, or prescriber concern for QT prolongation
- Uncorrected significant hypokalemia or hypomagnesemia until repleted and cleared
- Signs of serious allergic reaction, severe rash, rhabdomyolysis (muscle pain, weakness), or hepatitis
- Watery diarrhea with fever or suspected C. difficile infection pending evaluation
- Supratherapeutic INR or bleeding on warfarin until MDT review
- Acute worsening of myasthenia gravis symptoms
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Erythromycin is a classic macrolide with a heavy interaction footprint—medication passes must prioritize CYP3A4 substrates and QT risk before the first QID dose.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time, and formulation (base vs salt)
- Macrolide allergy reviewed; contraindicated co-therapy (simvastatin/lovastatin, cisapride, etc.) absent from MAR
- CYP3A4 substrates screened—especially theophylline, warfarin, colchicine, digoxin
- QT-prolonging MAR entries and electrolytes reviewed
2. Safety badge
CYP3A4 inhibitor — interaction and QT screening requiredLabeling documents fatal arrhythmias and serious CYP3A4 interactions at recommended doses—treat MAR review with the same rigor as institutional high-alert workflows.
3. Hold and question rules
- New tremor, tachycardia, or vomiting on theophylline → hold erythromycin and notify prescriber/pharmacist
- Simvastatin or lovastatin on MAR → do not administer erythromycin until clarified
- Palpitations or syncope → hold dose and obtain rhythm assessment per protocol
4. Critical teach-back questions
- “What new medicines must you check with the team before taking?” (Patient should say to ask prescriber/pharmacist before adding any drug during erythromycin.)
- “What muscle or heart symptoms need urgent review?” (Patient should name muscle pain, weakness, palpitations, or fainting.)
5. Care coordination
Pharmacist: CYP3A4 interaction review, theophylline level plan, statin contraindication check, warfarin INR plan
Prescriber: Alternative antibiotic if interaction or QT risk outweighs benefit; hepatotoxicity or CDAD management
🧠 Quick mental checklist
- Is theophylline, aminophylline, simvastatin, colchicine, warfarin, or digoxin on the MAR?
- What are today’s potassium, magnesium, theophylline level, and INR results?
- Any QT-prolonging drugs or cardiac history on the chart?
- Any macrolide allergy or prior erythromycin hepatotoxicity?
- Has the patient developed tremor, muscle pain, palpitations, jaundice, or watery diarrhea?
Erythromycin NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for erythromycin CYP3A4 interaction safety using a tabbed case (MAR, labs, history, nursing notes), then priority action, cue recognition (SATA), theophylline trend interpretation, documentation cloze, ordered response, and matrix urgency—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, history, and nursing note details for this case.
- Erythromycin 500 mg PO q12h — day 2 (first hospital dose yesterday for bronchitis)
- Theophylline ER 300 mg PO q12h — home dose continued
- Simvastatin 40 mg PO at bedtime — on MAR from admission
- Albuterol inhaler PRN — used twice overnight
- Admission theophylline level 14 mcg/mL (therapeutic)
- Today theophylline 28 mcg/mL (toxic range per protocol)
- CK 480 U/L (elevated); BMP otherwise unremarkable
- Potassium 4.0 mEq/L; magnesium 2.0 mg/dL
- 68-year-old with COPD and chronic bronchitis exacerbation
- Long-term theophylline therapy at home; no recent dose change documented
- Erythromycin started yesterday when sputum culture pending
- No known macrolide allergy
- Reports nausea, tremor, and palpitations since second erythromycin dose
- HR 118; fine hand tremor observed
- Pharmacy note on chart: “Erythromycin inhibits CYP3A4—review theophylline and statins”
- Patient states “I feel shaky like when my theophylline was too high years ago”
Answer key & rationale
Frequently asked questions
Why are CYP3A4 interactions the main nursing safety concern with erythromycin?
Labeling describes erythromycin as a moderate CYP3A4 inhibitor. Co-administration can raise levels of theophylline, simvastatin or lovastatin, colchicine, warfarin, and digoxin—with reports of theophylline toxicity, rhabdomyolysis, and increased anticoagulant effect. Erythromycin is contraindicated with lovastatin or simvastatin and with several QT-prolonging agents.
When should a nurse hold erythromycin?
Hold for hypersensitivity; concomitant terfenadine, astemizole, cisapride, pimozide, ergotamine, dihydroergotamine, lovastatin, or simvastatin; rising theophylline level or toxicity signs; QT symptoms; uncorrected hypokalemia or hypomagnesemia; hepatitis; serious rash; rhabdomyolysis symptoms; watery diarrhea with fever suggesting C. difficile; or supratherapeutic INR with bleeding on warfarin.
Does erythromycin interact with theophylline?
Yes. Labeling states erythromycin use in patients receiving high doses of theophylline may increase serum theophylline levels and cause theophylline toxicity. If toxicity or elevated levels occur, the theophylline dose should be reduced while the patient receives concomitant erythromycin.
What adverse effects matter most for nurses?
Priority concerns include dose-related GI effects (nausea, vomiting, diarrhea), CYP3A4 interaction toxicity, QT prolongation and torsades de pointes, hepatotoxicity, serious allergic and skin reactions, C. difficile-associated diarrhea, myasthenia gravis exacerbation, and infantile hypertrophic pyloric stenosis in infants.
Is erythromycin safe in pregnancy and breastfeeding?
Animal reproduction studies did not show teratogenicity at listed doses, but observational studies in humans reported cardiovascular malformations after early pregnancy exposure—use only if clearly needed. Erythromycin is excreted in human milk; caution is advised in nursing women per labeling.
References
- U.S. National Library of Medicine. Erythromycin tablet, film coated — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0277341c-8513-4317-9334-c242f97630c1
- U.S. National Library of Medicine. Ery-Tab (erythromycin) tablet — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b783a3b-881d-4dd3-953c-97011c962dae
- Drugs and Lactation Database (LactMed). Erythromycin. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK518982/
- U.S. National Library of Medicine. Erythromycin — MedlinePlus drug information.https://medlineplus.gov/druginfo/meds/a682381.html
- U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program.https://www.accessdata.fda.gov/scripts/medwatch/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.